Pediatric Motor Inflammatory Neuropathy: The Role of Antiphospholipid Antibodies

We report the clinical case of a nine-year-old girl who presented with progressive motor neuropathy, revealed via the detection of a higher delay in F-wave recording using digitalized nerve conduction/electromyography. Since the lupus anticoagulant (LAC) positivity, detected using diluted Russell viper venom time (dRVVT), switched to persistent serological anticardiolipin immunoglobulin G (IgG) positivity, a possible non-thrombotic antiphospholipid antibody (aPL)-related clinical manifestation was suspected, and intravenous immunoglobulin treatment (IVIG) was started. The IVIG treatment was well tolerated and the complete resolution of motor impairment was obtained after the third IVIG infusion. Our findings suggest that it could be useful to check for antiphospholipid antibodies in children with a rapid onset of progressive neurological signs in order to provide the beneficial use of IVIG in the treatment of pediatric aPL neurological conditions.

[1]  B. Myones,et al.  Diagnosis and treatment of antiphospholipid syndrome in childhood: A review. , 2017, Blood cells, molecules & diseases.

[2]  S. Kamphuis,et al.  European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative , 2017, Annals of the rheumatic diseases.

[3]  A. Verschueren.  Motor neuropathies and lower motor neuron syndromes. , 2017, Revue neurologique.

[4]  B. Myones,et al.  Pediatric Antiphospholipid Syndrome , 2015, Current Rheumatology Reports.

[5]  R. Manna,et al.  Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea , 2014, Lupus.

[6]  G. De Michele,et al.  Antiphospholipid-Related Chorea , 2012, Front. Neur..

[7]  R. Dale,et al.  Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies , 2011, Developmental medicine and child neurology.

[8]  W. Chung,et al.  Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy , 2010, Neurology.

[9]  R. Cimaz,et al.  The Ped-APS Registry: the antiphospholipid syndrome in childhood , 2009, Lupus.

[10]  T. Avčin,et al.  Review: Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome , 2007, Lupus.

[11]  E. Silverman,et al.  Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome , 2007 .

[12]  S. Mawson,et al.  Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. , 2006, Developmental medicine and child neurology.

[13]  D. D'cruz,et al.  Managing antiphospholipid antibodies and antiphospholipid syndrome in children. , 2006, Haematologica.

[14]  T. Hanafusa,et al.  Clinical manifestations of chronic inflammatory demyelinating polyneuropathy with anti‐cardiolipin antibodies , 2005 .

[15]  J. Chapman,et al.  CNS dysfunction in the antiphospholipid syndrome , 2003, Lupus.

[16]  M. Main,et al.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[17]  Y. G. Kim,et al.  Intravenous immunoglobulin protects against experimental thrombotic microangiopathy. , 2001, Kidney international.